Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05898932 · ClinicalTrials.gov registry record

Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes

A clinical trial of Benign Prostatic Hyperplasia, sponsored by Northwestern University.

Recruiting
Registry status
300
Enrollment target
1
Study location

NCT05898932: Recruiting study of Benign Prostatic Hyperplasia, sponsored by Northwestern University.

NCT05898932 is a study of Benign Prostatic Hyperplasia that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 300 participants, below the 542-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05898932, a study of Benign Prostatic Hyperplasia, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
300 participants
Enrollment target
1
Study location

Study Summary

The goal of this project is to use newly developed patient-reported outcomes to improve the clinical care of patients with benign prostatic hyperplasia. The use of new patient-centered tools will improve evaluation and clinical decision-making by including symptoms not commonly measured in men, such as urinary incontinence, and allow for more frequent assessment of lower urinary tract symptoms through remote surveillance. Through the use of care-coordination checklists, clinicians can be more responsive to post-treatment symptom changes, resulting in reduced bother from lower urinary tract symptoms and higher quality of life in patients with benign prostatic hyperplasia.

Primary Outcome

This is a single item that captures how much better or worse the person's bladder condition is relative to when they began treatment for BPH. The Patient Global Rating of Change (PGRC) scale ranges from "Very much worse" (1) to "Very much improved" (7), with higher scores indicating a better outcome.

Interventions

  • OTHER Medical Management
  • OTHER Surgical Management

Study Locations (1)

Illinois

  • NorthShore University HealthSystem Research Institute - Glenview

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2023-06-01
Est. Completion 2026-08
Northwestern University

1,209 total trials

What NCT05898932 shows while recruiting

NCT05898932 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 542-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (45% lower).

The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 2 interventions - of which Medical Management is the first listed.

NCT05898932 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05898932 about?

NCT05898932 is a clinical study titled "Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes". The goal of this project is to use newly developed patient-reported outcomes to improve the clinical care of patients with benign prostatic hyperplasia. The use of new patient-centered tools will improve evaluation and clinical decision-making by including symptoms not commonly measured in men, such...

What is the current status of trial NCT05898932?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-06-01. Estimated completion is 2026-08.

What conditions does trial NCT05898932 study?

This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.

What interventions are being tested in trial NCT05898932?

The interventions under investigation include: Medical Management (OTHER), Surgical Management (OTHER).

Who is sponsoring clinical trial NCT05898932?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05898932 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Benign Prostatic Hyperplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05898932's enrollment target sits among peer trials

300 8th of 29 higher than 22 of 29 other Benign Prostatic Hyperplasia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05898932, the US trial registry maintained by the National Library of Medicine. NCT05898932 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.